Default Caption Image

AI-Based Pathology Diagnosis Tool in Development Detects 7 Types of Gastric Cancer

August 29, 2022

Image data from multiple hospitals improves the tool’s versatility and accuracy

WALTHAM, Mass., (Aug. 29, 2022) Evident, a wholly owned subsidiary of Olympus Corporation, announced the latest results from its ongoing joint research program to create an AI-based pathology diagnostic tool at the 20th annual meeting of the Japanese Society of Digital Pathology. The results show the diagnostic tool in development succeeded in expanding its AI detection to seven types of gastric cancer, highlighting its versatility for a range of pathology applications. 

Meeting the Demand for Diagnostic Tools

There is an increasing demand for diagnostic tools that can help reduce the workload of pathologists. To meet this need, Evident began a collaboration with the National Hospital Organization Kure Medical Center and Chugoku Cancer Center in 2017 to develop an AI-based pathology diagnosis tool. 

The first testing phase1 showed the diagnostic tool could successfully identify adenocarcinoma tissue from pathology whole-slide images. As part of the second research phase2 that began in November 2020, the tool was tested on 2,717 pathology whole-slide images provided by six hospitals3 in Japan to improve its versatility and accuracy. 

Results from the Second Research Phase

By significantly increasing the amount of image data through collaboration with the hospitals, the diagnostic tool improved its AI detection of adenocarcinoma of tubular and poorly differentiated types and expanded its AI detection to identify other gastric cancers. It achieved a false negative rate of 0 to 2.5% in seven types of gastric cancer: adenocarcinoma, of tubular, papillary, mucinous and poorly differentiated types, gastrointestinal stromal tumor, MALT lymphoma, and diffuse large B-cell lymphoma. A common AI discrimination threshold*4 was set for all hospitals, demonstrating the improved versatility of the software. 

As the second research phase continues, Evident aims to further refine the tool to prepare it for commercial use. The goal of this program is to deliver an AI pathology diagnosis software that can assist pathologists by 2023. 


At Evident, we are guided by the scientific spirit—innovation and exploration are at the heart of what we do. Committed to making people’s lives healthier, safer and more fulfilling, we support our customers with solutions that solve their challenges and advance their work; whether it’s researching medical breakthroughs, inspecting infrastructure, or exposing hidden toxins in consumer products.

Evident Industrial’s solutions range from microscopes and videoscopes to nondestructive testing equipment and X-ray analyzers for maintenance, manufacturing and environmental applications. Backed by state-of-the-art technologies, Evident products are widely used for quality control, inspection, and measurement.  

Evident Life Science empowers scientists and researchers through collaboration and cutting-edge life science solutions. Dedicated to meeting the challenges and supporting the evolving needs of its customers, Evident Life Science advances a comprehensive range of microscopes for pathology, hematology, IVF and other clinical applications as well as for research and education.

For more information, visit

About the National Hospital Organization Kure Medical Center and Chugoku Cancer Center

The Kure Medical Center and Chugoku Cancer Center is one of the core hospitals in western Japan. The pathology department performs a large number of pathological diagnoses on a daily basis, and also conducts pathological diagnosis of community medicine in cooperation with Hiroshima University and the Kure Medical Association Hospital. In addition, as a tumor pathology laboratory, they are conducting cutting-edge academic research, including the field of digital pathology. And as a member of the National Hospital Organization Pathology Council, they are also actively conducting clinical pathology research.

Evident and the Evident logo are trademarks of Evident Corporation or its subsidiaries.

1 Learn more about the first phase
2 Learn more about the second phase
3 National Hospital Organization Kure Medical Center and Chugoku Cancer Center, National Hospital Organization Osaka National Hospital, National Hospital Organization Shikoku Cancer Center, National Hospital Organization Nagasaki Medical Center, Hiroshima Memorial Hospital, and Kure Medical Association Hospital. 
4 A value that divides a gastric biopsy into positive and negative.


Back to What's New

Not available in your country.
Sorry, this page is not available in your country
Sorry, this page is not available in your country